CliffBio
small molecule

ATROVENT HFA

IPRATROPIUM BROMIDE

Loss of exclusivityJanuary 2030latest FDA-listed patent expiry
CompanyBoehringer Ingelheim →View the full company profile on CliffBio

Drug detail

Brand nameATROVENT HFA
Active ingredientIPRATROPIUM BROMIDE
Strength0.021MG/INH
Dosage formAEROSOL, METERED
RouteINHALATION
ModalitySmall molecule
FDA approvalNovember 2004
Marketing statusRX

Listed patents

PatentExpiresType
8474447January 2030product

More from Boehringer Ingelheim

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ATROVENT HFA patent cliff — loss of exclusivity January 2030 | CliffBio